NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that nearly 200 employees participated in the Company’s second annual “Arvinas Impact Day,” a